Re: $ Due to RVX

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fouremm

Rank: President [?]

Points: 3330 [?]

Votes: 34 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: $ Due to RVX

in response to

Re: $ Due to RVX

BearDownAZ

posted on Mar 17, 2016 02:43PM

I think BDAZ is correct in his assessment. I imagine we will see the commencement of the trial, the announcement of the reorganization and perhaps (hopefully) a financing occur all at the same time.

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply